The IASLC (International Association for the Study of Lung Cancer) 2022 WCLC (World Conference on Lung Cancer) will be held in Vienna, Austria from August 6 to 9, 2022, at which 31 EGFR-TKI related results with Chinese mainland experts as first or correspondent authors will be released, including 21 results related to aumolertinib mesilate tablets (trade name: Ameile) independently developed by Hansoh Pharma, accounting for 68% of the total and ranked first among all EGFR-TKIs. WCLC is the world's largest multidisciplinary oncology conference dedicated to lung cancer and other thoracic malignancies. At each session, results from several major clinical studies are announced and clinical practices are updated accordingly. In 2022, WCLC will once again provide an offline communication platform for thousands of professionals from more than 100 countries worldwide to discuss the latest advances in the treatment of lung cancer and other thoracic malignancies. Aumolertinib is China's first original third-generation EGFR-TKI independently developed by Hansoh Pharma and also the world's first third-generation EGFR-TKI with median progression-free survival (mPFS) exceeding one year (for second-line use), and has been widely recognized by international authorities for its superior efficacy and safety profile. In May 2022, the results of the AENEAS study on aumolertinib were published in the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, and the latest subgroup data of brain metastases were presented at the ASCO (American Society of Clinical Oncology) annual meeting, once again stunning the international oncology community. In order to further tap the therapeutic potential of aumolertinib in the segment of lung cancer and benefit more NSCLC patients worldwide, Hansoh Pharma is still working to explore the clinical value of aumolertinib based on its current successful R&D experience, including multiple clinical studies on the first-line treatment of NSCLC with sensitive mutations and the adjuvant treatment of NSCLC and other indications with Ameile combined with platinum-containing dual-agent chemotherapy, which will provide more NSCLC patients with a full range of multidimensional dosing options from early to advanced stage, from perioperative adjuvant therapy, second- and post-line therapy to first-line therapy. At this WCLC, up to 21 abstracts on aumolertinib will be released, including 7 regular abstracts (study data), 3 case reports and 11 ongoing clinical studies, which will bring the latest research progress of aumolertinib in targeted combination therapy (NSCLC) and brain (membrane) metastasis therapy.  【Regular Abstracts】EP08.02-003 Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared AnalysisY. Li, Z.Y. Pan, Y. Zhang, L. LiTianjin Key Laboratory of Brain Science and Tianjin Medical University Cancer Institute and Hospital and Key Laboratory of Cancer Prevention and Therapy, Tianjin/CNDescription: This is a phase II trial in untreated patients with advanced NSCLC EGFR-sensitizing mutation and performance status of 0 to 2. Approximately 42 patients will be recruited. Patients are treated with aumolertinib 110mg orally perday plus pemetrexed 500mg/m2 and carboplatin area undercurve 5 intravenously every 3weeks for four cycles, followed by maintenance pemetrexed. The primary endpoint is mPFS, secondary endpoints include objective response rate (ORR), disease control rate(DCR), overall survival(OS) and toxicity. Circulating tumor DNA (ctDNA) EGFR clearance is also investigated. Form 7 November 2020 to 7 November 2021, 34 patients were enrolled and evaluated. Preliminary overall ORR was 88.2% (30/34) and mPFS was not reached so far. The most common adverse events (AE, all grades) were neutropenia, fatigue, anorexia. 2 patients were intolerant to chemotherapy and had been receiving aumolertinib monotherapy since then. In this study, 28 patients received ctDNA EGFR testing during treatment and 22 of them (78.6%) had at least one ctDNA EGFR clearance after 2 or 4 cycles. The ORRs of patients with ctDNA EGFR cleared and the ones with no clearance were 91% and 33% respectively.Keywords: NSCLC, Aumolertinib, ctDNAEP08.02-004 Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients with Brain Metastases: Primary Effi cacy and Safety Data from the ARTISTRYH. WangThe Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou/CNDescription: ARTISTRY (NCT04778800) is an ongoing dose-escalation study evaluating third-generation EGFR-TKI aumolertinib (formerly almonertinib; HS-10296) in three cohorts of EGFR-mutant NSCLC patients with brain/leptomeningeal metastases. In cohort 1, treatment-naïve EGFR-mutant NSCLC patients with brain parenchyma metastases received aumolertinib 110mg orally once daily. The dose was then escalated to 165mg in case of only intracranial progression. Assessments were performed every 4 weeks and then every 8 weeks after 2 consecutive disease control until extracranial progression as per RECIST v1.1. Endpoints included intracranial ORR (iORR), intracranial DCR (iDCR), and safety. At data cut-off (March 1, 2022), a total of 14 patients were enrolled and the median follow-up time was 7.8 months (range, 2.4-15.1), of which 12 patients with ≥1 measurable and/or non-measurable CNS lesion at baseline were included in the CNS full analysis set (cFAS) and 10 patients with ≥1 measurable CNS lesion at baseline were included in the CNS evaluable for response set (cEFR). The iORR was 66.7% (8/12; 95% CI: 34.9-90.1) in the cFAS and 80.0% (8/10; 95% CI:44.4-97.5) in the cEFR. The iDCR was 100% in both cFAS and cEFR. In the 165mg group, the iORR and iDCR were 0 (0/3) and 100% (3/3), respectively. The most common grade 1-2 adverse events (AEs) in all patients were anemia (3/14; 21.4%), alanine aminotransferase increased (3/14; 21.4%), fatigue (2/14; 14.3%), and edema limbs (2/14; 14.3%). No grade ≥3 AEs were observed.Keywords: aumolertinib, EGFR-TKI, brain metastasesEP08.02-038 Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain MetastasisS. Fu1, J. Liu1, P. Fu2, H. Li3, X. Yang3, C. Xie4, J. Zhang41Shandong Cancer Hospital and Institute Affiliated to Shandong University, jinan/CN, 2Jinan Zhangqiu District People’s Hospital, Jinan/CN, 3The Affiliated Hospital of Qingdao University, Qingdao/CN, 4Shandong Cancer Hospital and Institute Affiliated to Shandong University,, Jinan/CNDescription: Springlung150B (ChiCTR2000035591) is a study to explore the efficacy and safety of aumolertinib plus bevacizumab and pemetrexed in first-line treatment of patients with EGFRm NSCLC and BMs. NSCLC patients with EGFRm and BMs received oral aumolertinib (110 mg QD) plus intravenous bevacizumab (7.5 mg/kg) and pemetrexed (500mg/m2) for 4 cycles in first-line treatment, then their maintenance treatment were adjusted for one of three modes: aumolertinib, aumolertinib + bevacizumab, or aumolertinib +pemetrexed. The primary endpoints are progression-free survival (PFS) and intracranial PFS, and secondary endpoints include objective response rate(ORR), intracranial ORR(iORR), and safety. The data cutoff date was Nov 30, 2021. Form Feb 2020 to Nov 2021, 10 patients were recruited. The primary endpoint was not reached, and the secondary endpoints were analyzed for the 4 cycles first-line treatment. Confirmed partial response (PR) were achieved in 8 patients and stable disease (SD) in 2 patients, the ORR was 80% and disease control rate (DCR) was 100%. 9 patients (90%) had intracranial response, of which 2 had complete response, 7 had PR and 1 had SD, the iORR was 90% and iDCR was 100%. The most common adverse event was rash (40%), and no grade 3-4 serious events occurred.Keywords: EGFR mutant NSCLC, Brain Metastasis, Aumolertinib combination therapyEP08.02-050 A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal MetastasisS. FangNanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing/CNDescription: This is a retrospectively study to analyse the results of aumolertinib combined with bevacizumab treatment in five patients with EGFRm NSCLC and LM. We included 5 patients with EGFRm NSCLC and LM at Nanjing Chest Hospital, whose median age was 54 years, predominantly female (80%). EGFR mutations included exon 21 L858R mutation, T790M mutation, exon 19 deletion combined with TP53 mutation, and c-MET amplification. Prior to combination therapy, the mean number of lines of therapy was 1.2. The median length of therapy for Aumolertinib in combination with bevacizumab was 11 months, and the median PS score was 4 before treatment and 1 after combination therapy. To assess the clinical efficacy of a regimen of the third-generation TKI Aumolertinib (110 mg/day) in combination with bevacizumab (7.5 mg/kg, 21-day cycle) in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and LM. 2 patients (40%) had complete remission (CR) of LM lesions, 3 patients (60%) had partial remission (PR), and the intracranial objective remission rate (iORR) was 100%. 1 patient had stable disease (SD) in the whole lesion, 4 patients achieved PR, an overall ORR of 80%, and a disease control rate (DCR) of 100%. After 2 months of combination therapy, magnetic resonance imaging (MRI) of the brain was performed in all 5 patients and showed significant reduction of LM, with continued remission of LM as treatment continued, and no progression of systemic or LM lesions in any of the 5 patients, with a good safety profile and still under close follow-up.Keywords: Aumolertinib, NSCLC, leptomeningeal metastasisEP08.02-069 A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal MetastasesS. Huang, L. Li, N. Yan, H. Zhang, S. Guo, Q. Guo, D. Geng, X. LiThe First Affiliated Hospital of Zhengzhou University, Zhengzhou/CNDescription: In this study, we researched the efficacy of aumolertinib monotherapy or combination therapy with EGFR-mutated NSCLC leptomeningeal metastases. Retrospective analysis of 11 EGFR-mutated NSCLC patients with LMs from April 2020 to December 2021 in the first Affiliated Hospital of Zhengzhou university. Patients were administrated almonertinib monotherapy (110mg QD) or combined with chemotherapy (chemotherapy or bevacizumab) until progression or intolerance. The primary endpoint was progression free survival (PFS). The median age was 60.5 years (range, 49-76years), 45% were female, and 72.7% were never-smokers, 36% were 19del. The median follow-up were 8.5 months, all the patients had progressed. The confirmed partial response (PR) were 6 (54.5%) patients and stable disease (SD) were 3 (27.3%) patients, the ORR was 54.5% (6/11) and the DCR was 81.8 % (9/11). The median PFS for all patients was 8.1 months. In subgroup analysis, the median PFS of 19del or L858R patients were 12 or 8 respectively, and median PFS of EGFR positive mutation combined with TP53 were 8 months and without TP53 were 13 months.Keywords: Aumolertinib, Leptomeningeal Metastases, EGFR-TKIEP08.02-154 Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II TrialH. Chen, M. Lin, Y. Luo, H. Chen, M. Liu, S. Li, Z. YangAffiliated Hospital of Guangdong Medical University, Zhanjiang/CNDescription: This is a single-arm, single-center, phase II clinical study to explore a new mode of treatment with third-generation EGFR-TKI combined with oral anti-angiogenic drugs, and to provide new ideas for further prolonging the progression-free survival time of first-line treatment of advanced NSCLC patients with EGFR mutations. Untreated patients with advanced EGFR-mutant NSCLC receive aumolertinib 110mg orally QD plus anlotinib 12mg orally QD. Anlotinib is continuously used for 2 weeks and then stopped for 1 week, that is, a 3-week (21-day) cycle program. The primary endpoint was PFS, secondary endpoints included objective response rate (ORR), disease controlRate (DCR), overall survival (OS), duration of response (DoR) and safety. From Jan, 2020 to Feb, 2021, 11 patients were recruited. The median age was 67 years, 8 (72.7%) were male, and 10 (90.0%) were multiple metastases which include 7 (63.6%) brain metastases. Of 11 response-evaluable subjects, all patients achieved partial response (PR) as their best response, so overall ORR was 100% (11/11). 7 patients with brain metastases were evaluated for intracranial target lesions, with 5 achieving PR and 2 SD as their best response. iORR was 71.4% (5/7) and iDCR was 100% (7/7). No patients discontinued the drug due to adverse reactions. This study is currently ongoing and the primary endpoint has not been reached so far.Keywords: Aumolertinib, Anlotinib, NSCLCEP08.02-169 Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive MutationD.S. Zhong, F.L. Meng, L. Zhang, Q. Ma, X. Liu, X. Wang, X. YangTianjin Medical University General Hospital, Tianjin/CNDescription: This study was conducted to evaluate aumolertinib plus bevacizumab for untreated NS-NSCLC patients with EGFR sensitizing mutations. The study was expected to enroll 36 eligible patients who would receive oral aumolertinib (110 mg QD) plus intravenous bevacizumab (15 mg/kg Q3W) in first-line treatment and been stratified according to sex, smoking history, stage, EGFR mutation status and brain metastasis (BMs). The primary endpoint was PFS% at 12 months. the secondary endpoints were objective response rate (ORR), overall survival (OS) and progress free survival (PFS). Form Sep 16, 2020 to Sep 16, 2021, 19 patients were enrolled, and at a median follow-up 9.3 months (0.5m-11.3m), 15 patients were evaluated. Their ORR was 66.7% (10/15), with an average reduction of the target lesions of 37.0%. CNS metastases ORR was 80.0% (8/10), and for those with measureable intracranial lesions, intracranial ORR was 87.5% (7/8), the average reduction of the intracranial target lesions was 48.8%. the most common AEs were creatine phosphokinase increased(27.8%), proteinuria(22.2%), AST/ALT increased(22.2%) and weak(16.7%). 3 patients had grade 3 AEs and one patient stopped bevacizumab due to chest pain(5.6%).Keywords: NSCLC, Aumolertinib, Bevacizumab 【Case Reports】EP08.02-002 Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial PneumoniaJ. TanSuzhou Municipal Hospital, Suzhou/CNDescription: An 81-year-old male patient with NSCLC was considered to have a tumor diagnosis of stage IB adenocarcinoma (pT2aN0M0) in 2013. Three years after surgical treatment, PET-CT imaging revealed multiple enlarged lymph nodes in the neck and genetic testing of the nodes suggested EGFR exon 19 deletion.This patient has undergone chemotherapy, 1st generation EGFR-TKI treatment, 3rd generation EGFR-TKI treatment, and a new 3rd generation EGFR-TKI aumolertinib re-challenge. Chemotherapy was treated with standard dose pemetrexed combined with cisplatin for 1 course, then changed to gefitinib 250 mg/day for 1 month due to poor efficacy, with partial remission, then changed to icotinib due to recurrent drugrelated liver injury, with first generation EGFR-TKIs for 38 months in remission, with T790M mutation after disease progression. He was switched to 80 mg/day osimertinib, which was in partial remission, but developed interstitial pneumonia after 4 months of treatment, which was remitted after discontinuation, but recurred after re-dosing, so he was switched to 110 mg/day aumolertinib targeted therapy with stable efficacy and no recurrence of interstitial pneumonia.Keywords: EGFR-TKI, Interstitial pneumonia, re-challengeEP08.02-039 An Eff ective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using AumolertinibX. Zhang, Y. Wu, Y. Hu, S. ZhangBeijing Chest Hospital,Capital Medical University, Beijing/CNDescription: A 53 year-old Chinese women with no smoking history presented with severe headache and projectile vomiting in August 2020. Lumbar puncture pressure ranged from 190 to 320mmH2O at that time. She was diagnosed as stage IV (cT1N2M1) lung adenocarcinoma with leptomeningeal, mediastinal lymph node, liver, multiple bone metastases. The ECOG PS was 4 before she underwent anti-tumor therapies. Biopsy sample of peripheral blood and cerebrospinal fluid (CSF) cell-free DNA (cfDNA) was subjected to fluorescence PCR. The results showed EGFR 19-del mutation. Since enhanced mannitol treatment was ineff ective, an exploratory strategy was used for this patient. She received aumolertinib 220mg per day on September 15,2020, as soon as the EGFR mutation status was confirmed. Three days later, as her symptoms of intracranial hypertension were relieved and her consciousness recovered, the dose of aumolertinib was adjusted to 110mg orally per day. A repeat lumbar puncture pressure went down to 120mmH2O 12 days after she started to receive aumolertinib. On September 28, it began to perform combination strategy with bevacizumab 400mg every three weeks. The ECOG PS was 1 after initial anti-tumor treatment. The best effect of lung and intracranial lesions both have reached PR. The disease was under control until December 15, 2021, as clinical and imaging progression in right pulmonary lymph-vessel and bone metastases occurred. PFS was 15 months. This patient continued to take chemotherapy and antiangiogenic therapy as subsequent treatment. No adverse events were observed during treatment.Keywords: EGFR-mutated NSCLC, leptomeningeal metastases, high-dose aumolertinibEP08.02-095 Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with AumolertinibC. Liu, H. Zhu, S. NuerlanThe Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi/CNDescription: A 53-year-old female patient presented on September 26, 2019 with an intermittent cough for 5 months and a mass in the left lung for 3-month. CT showed a soft tissue mass in upper lobe of her left lung, and pathology revealed poorly diff erentiated adenocarcinoma of left lung. The patient was diagnosed with left upper lobe adenocarcinoma stage IVB (cT2aN3M1c), accompanied by bilateral hilar, mediastinal lymph nodes, both lungs, and multiple bone metastases. Lung tumor biopsy was performed for genetic testing and an EGFR exon 19 deletion and mutations of TP53 were observed. In the first line treatment, the patient received gefitinib and attained a PR. However, 9 months later, she developed multiple new metastatic lesions in both lungs. Genetic testing analysis showed an EGFR exon 19 deletion and mutations of TP53 and ERBB2 20ins.Due to the lack of effective treatment method, aumolertinib, a novel third-generation EGFR-TKI approved in China 2020, was given 110 mg per day orally. After 3-month treatment, both the primary tumor and the lung metastases shrank, and the patient obtained PR. Unfortunately, another 4 months later, chest CT revealed the primary lesion increased, and multiple lymph node metastases appeared in her neck and clavicle area. Subsequently, a new combination strategy was adopted: aumolertinib combined with Pemetrexed plus bevacizumab. One month later, the patient’s lymph nodes in the neck and clavicle area shrank, and her primary lesions and recurrent tumors shrank as well. Then she received this treatment plan for 7 months, and her response evaluation indicated stable disease. After that, she continued to take a combination treatment of aumolertinib and bevacizumab.Up to now, this pattient has achieved a PFS of more than 29 months and she is still under a close follow-up. Of note, there were only milder drug-related adverse events during treatment, mostly grade 1, including dysgeusia and hepatotoxicity, as well as epistaxis and hypertension associated with bevacizumab.Keywords: NSCLC, EGFR TKI, complicated mutation 【Ongoing Clinical Studies】EP08.02-001 Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain MetastasesY. WangChongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer H, Chongqing/CNKeywords: brain metastases, Aumolertinib, radiotherapyEP05.02-009 Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)W. Liang1, E. Xu2, J. Zhao3, M. Wang4, Z. Zhang5, Y. Liang 6, C. Cheng7, G. Wang8, C. Zhong9, Z. Liang10, X. Chen11, B. Zheng12,Y. Huang13, J. Hu14, L. Xu15, M. Xie16, N. Liang17, S. Xu18, J. Liu19, L. Wei20, Z. Peng21, G. Zhang22, S. Zhang23, S. Xu24, J. He11The First Affiliated Hospital of Guangzhou Medical University, Guangzhou/CN, 2General Hospital of Southern Theater Command, Guangzhou/CN, 3Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou/CN, 4Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou/CN, 5Jieyang People’s Hospital, Jieyang/CN, 6Zhongshan People’s Hospital, Zhongshan/CN, 7First Affi liated Hospital of Sun Yat-sen University, Guangzhou/CN, 8People’s Hospital of Shenzhen, Shenzhen/CN, 9Shenzhen Hospital, Southern Medical University, Shenzhen/CN, 10Affiliated Hospital of Guangzhou Medical University, Guangzhou/CN, 11Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou/CN, 12Fujian Medical University Union Hospital, Fuzhou/CN, 13Yunnan Cancer Hospital & The Third Affiliated Hospital of KunmingMedical University & Yunnan Cancer Center, Kunming/CN, 14The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou/CN,15Jiangsu Cancer Hospital, Nanjing/CN, 16The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei/CN, 17Peking Union Medical CollegeHospital, Beijing/CN, 18Tianjin Medical University General Hospital, Tianjin/CN, 19The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang/CN, 20Henan Provincial People’s Hospital, Zhengzhou/CN, 21Shandong Provincial Hospital, Jinan/CN, 22The First Affi liated Hospital of Xi’an Jiaotong University, Xian/CN, 23Shengjing Hospital of China Medical University, Shenyang/CN, 24The First Hospital of ChinaMedical University, Shenyang/CNKeywords: aumolertinib, stage IIIA NSCLC, neoadjuvantEP05.02-016 Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR MutationY.ZhangDepartment of Oncology, The People’s Hospital of Guizhou Province, Guiyang/CNKeywords: NSCLC, adjuvant chemotherapy/radiotherapy, AumolertinibEP08.02-021 A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain MetastasesY. Tang, L. Zhu, M. Zhang, B. Wang, X. Xu, S. Ma, B. XiaAffiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou/CNKeywords: Aumolertinib, Radiotherapy, Brain MetastasesEP08.02-051 High-dose Aumolertinib as First-line Treatment in Patients with Brain Metastases Associated with EGFR Mutated NSCLCY. FanCancer Hospital of The University of Chinese Academy of Sciences, Hangzhou/CNKeywords: NSCLC, EGFR TKI, Brain MetastasesEP08.02-057 Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after ResistanceL. Feng, Z. Yu, J. Wang, X. Yang, Q. QiThe Affiliated Hospital of Qingdao University, Qingdao/CNKeywords: resistance mechanisms, Aumolertinib, real-world studyEP08.02-067 Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain MetastasesM. HuangDepartment of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center,West China Hospital, Sichuan University, Chengdu/CNKeywords: aumolertinib, icotinib, brain metastasesEP08.02-077 Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor GenesJ. WangCancer Hospital Chinese Academy of Medical Sciences, Beijing/CNKeywords: NSCLC, concomitant mutations, EGFR-TKIEP08.02-094 Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm TrialG. Lin1, Q. Chu21Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou/CN, 2Tongji Hospital of Tongji Medical College, Huazhong University ofScience and Technology, Wuhan/CNKeywords: aumolertinib, EGFR-TKI, adenosquamous carcinomaEP08.02-137 Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib TreatmentS. LuShanghai Chest Hospital, Shanghai/CNKeywords: Osimertinib, Intolerant, AumolertinibEP08.03-001 A Clinical Study on the Safety and Effi cacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal OligometastasesC. HeThe Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou/CNKeywords: Aumolertinib, SBRT, oligometastases 

The details of aumolertinib abstracts to be released at this WCLC can be found at://library.iaslc.org/conference-program?product_id=25 For the 21 aumolertinib abstracts, posters with further information will be released during the conference, so please stay tuned!